{"PubmedArticle": [{"MedlineCitation": {"InvestigatorList": [], "SpaceFlightMission": [], "CitationSubset": ["IM"], "KeywordList": [["COPD", "Respimat\u00ae Soft Mist Inhaler\u2122", "chlorofluorocarbons", "pressurized metered-dose inhaler"]], "GeneralNote": [], "OtherAbstract": [], "OtherID": [], "PMID": "23658481", "DateCompleted": {"Year": "2013", "Month": "11", "Day": "07"}, "DateRevised": {"Year": "2021", "Month": "10", "Day": "21"}, "Article": {"Language": ["eng"], "ELocationID": ["10.2147/COPD.S31246"], "ArticleDate": [{"Year": "2013", "Month": "04", "Day": "30"}], "Journal": {"ISSN": "1178-2005", "JournalIssue": {"Volume": "8", "PubDate": {"Year": "2013"}}, "Title": "International journal of chronic obstructive pulmonary disease", "ISOAbbreviation": "Int J Chron Obstruct Pulmon Dis"}, "ArticleTitle": "Efficacy and safety of eco-friendly inhalers: focus on combination ipratropium bromide and albuterol in chronic obstructive pulmonary disease.", "Pagination": {"StartPage": "221", "EndPage": "230", "MedlinePgn": "221-30"}, "Abstract": {"AbstractText": ["Chronic obstructive pulmonary disease (COPD) is a major cause of morbidity and mortality and its treatment is critical to improve quality of life, reduce symptoms, and diminish the frequency of COPD exacerbations. Due to the harmful environmental effects of pressurized metered-dose inhalers (pMDIs) containing chlorofluorocarbons (CFCs), newer systems for delivering respiratory medications have been developed.", "A search of the literature in the PubMed database was undertaken using the keywords \"COPD,\" \"albuterol,\" \"ipratropium bromide,\" and \"Respimat\u00ae Soft Mist Inhaler\u2122\"; pertinent references within the identified citations were included. The environmental effect of CFC-pMDIs, the invention of the Respimat\u00ae Soft Mist Inhaler\u2122 (SMI) (Boehringer Ingelheim, Ingelheim, Germany), and its use to deliver the combination of albuterol and ipratropium bromide for the treatment of COPD were reviewed.", "The adverse environmental effects of CFC-pMDIs stimulated the invention of novel delivery systems including the Respimat SMI. This review presents its development, internal mechanism, and use to deliver the combination of albuterol and ipratropium bromide.", "CFC-pMDIs contributed to the depletion of the ozone layer and the surge in disorders caused by harmful ultraviolet B radiation. The banning of CFCs spurred the development of novel delivery systems for respiratory medications. The Respimat SMI is an innovative device that produces a vapor of inhalable droplets with reduced velocity and prolonged aerosol duration that enhance deposition within the lower airway and is associated with improved patient satisfaction. Clinical trials have demonstrated that the Respimat SMI can achieve effects equivalent to pMDIs but with lower medication doses. The long-term safety and efficacy remain to be determined. The Respimat SMI delivery device is a novel, efficient, and well-received system for the delivery of aerosolized albuterol and ipratropium bromide to patients with COPD; however, the presence of longer-acting, less frequently dosed respiratory medications provide patients and providers with other therapeutic options."]}, "AuthorList": [{"AffiliationInfo": [{"Identifier": [], "Affiliation": "Pulmonary, Critical Care, and Sleep Medicine Division, Cincinnati Veterans Affairs Medical Center, Cincinnati, OH 45220, USA. ralph.panos@va.gov"}], "Identifier": [], "LastName": "Panos", "ForeName": "Ralph J", "Initials": "RJ"}], "PublicationTypeList": ["Journal Article", "Review"]}, "MedlineJournalInfo": {"Country": "New Zealand", "MedlineTA": "Int J Chron Obstruct Pulmon Dis", "NlmUniqueID": "101273481", "ISSNLinking": "1176-9106"}, "ChemicalList": [{"RegistryNumber": "0", "NameOfSubstance": "Bronchodilator Agents"}, {"RegistryNumber": "0", "NameOfSubstance": "Chlorofluorocarbons"}, {"RegistryNumber": "0", "NameOfSubstance": "Drug Combinations"}, {"RegistryNumber": "GR88G0I6UL", "NameOfSubstance": "Ipratropium"}, {"RegistryNumber": "QF8SVZ843E", "NameOfSubstance": "Albuterol"}], "MeshHeadingList": [{"QualifierName": ["chemistry", "therapeutic use"], "DescriptorName": "Albuterol"}, {"QualifierName": ["chemistry", "therapeutic use"], "DescriptorName": "Bronchodilator Agents"}, {"QualifierName": ["adverse effects"], "DescriptorName": "Chlorofluorocarbons"}, {"QualifierName": [], "DescriptorName": "Drug Combinations"}, {"QualifierName": ["trends"], "DescriptorName": "Equipment Design"}, {"QualifierName": [], "DescriptorName": "Humans"}, {"QualifierName": ["chemistry", "therapeutic use"], "DescriptorName": "Ipratropium"}, {"QualifierName": ["standards"], "DescriptorName": "Metered Dose Inhalers"}, {"QualifierName": ["prevention & control"], "DescriptorName": "Ozone Depletion"}, {"QualifierName": [], "DescriptorName": "Patient Satisfaction"}, {"QualifierName": ["drug therapy"], "DescriptorName": "Pulmonary Disease, Chronic Obstructive"}, {"QualifierName": ["instrumentation", "methods", "trends"], "DescriptorName": "Respiratory Therapy"}, {"QualifierName": [], "DescriptorName": "Treatment Outcome"}]}, "PubmedData": {"ReferenceList": [{"ReferenceList": [], "Reference": [{"Citation": "Global Initiative for Chronic Obstructive Lung Disease (GOLD): Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Pulmonary Disease 2013Available from: http://www.goldcopd.orgAccessed Dec 2012"}, {"Citation": "Barnes PJ, Celli BR. Systemic manifestations and comorbidities of COPD. Eur Respir J. 2009;33(5):1165\u20131185.", "ArticleIdList": ["19407051"]}, {"Citation": "Decramer M, Rennard S, Troosters T, et al. COPD as a lung disease with systemic consequences \u2013 clinical impact, mechanisms, and potential for early intervention. COPD. 2008;5(4):235\u2013256.", "ArticleIdList": ["18671149"]}, {"Citation": "Agusti A, Soriano JB. COPD as a systemic disease. COPD. 2008;5(2):133\u2013138.", "ArticleIdList": ["18415812"]}, {"Citation": "Fabbri LM, Luppi F, Begh\u00e9 B, Rabe KF. Complex chronic comorbidities of COPD. Eur Respir J. 2008;31(1):204\u2013212.", "ArticleIdList": ["18166598"]}, {"Citation": "van Eeden SF, Sin DD. Chronic obstructive pulmonary disease: a chronic systemic inflammatory disease. Respiration. 2008;75(2):224\u2013238.", "ArticleIdList": ["18042978"]}, {"Citation": "Midgley T, Jr, Heene AL. Organic fluorides as refrigerants. Ind Eng Chem. 1937;22(5):542\u2013545."}, {"Citation": "Zhong W.History of CFCs as refrigerants Accessed http://zwhudson.myweb.uga.edu/chem8290/replacement%20of%20CFCs%20as%20refrigerants.htmAccessed March 11, 2013"}, {"Citation": "Tsai WT. An overview of environmental hazards and exposure risk of hydrofluorocarbons (HFCs) Chemosphere. 2005;61(11):1539\u20131547.", "ArticleIdList": ["15936055"]}, {"Citation": "Lovelock JE. Atmospheric fluorine compounds as indicators of air movements. Nature. 1971;230:379."}, {"Citation": "Leach CL. The CFC to HFA Transition and its impact on pulmonary drug development. Respir Care. 2005;50(9):1201\u20131206.", "ArticleIdList": ["16122403"]}, {"Citation": "Rowland FS. Stratospheric ozone depletion. Philos Trans R Soc Lond B Biol Sci. 2006;361(1469):769\u2013790.", "ArticleIdList": ["PMC1609402", "16627294"]}, {"Citation": "Farman JS, Gardiner BG, Shanklin JD. Large losses of total ozone in Antarctic reveal seasonal ClOx/NOx interaction. Nature. 1985;315:207\u2013210."}, {"Citation": "Kerr RA. Another deep Antarctic ozone hole. Science. 1990;250(4979):370.", "ArticleIdList": ["17793009"]}, {"Citation": "Ozone hole through the years [web page on the Internet] Greenbelt, MD: Earth Observatory; 2011Available from: http://earthobservatory.nasa.gov/IOTD/view.php?id=49040Accessed Dec 2012"}, {"Citation": "Molina MJ, Rowland FS. Stratospheric sink for chlorofluoromethanes: chlorine atom-catalysed destruction of ozone. Nature. 1974;249:810\u2013814."}, {"Citation": "Butt AT, Kamat D, Pansare M. Final count down to hfa albuterol inhalers: are we ready as yet? Clin Pediatr (Phila) 2009;48(2):131\u2013134.", "ArticleIdList": ["19015282"]}, {"Citation": "Gribben J. The Hole in the Sky: Man\u2019s Threat to the Ozone Layer. London: Corgi; 1987."}, {"Citation": "Rogers HW, Weinstock MA, Harris AR, et al. Incidence estimate of nonmelanoma skin cancer in the United States, 2006. Arch Dermatol. 2010;146(3):283\u2013287.", "ArticleIdList": ["20231499"]}, {"Citation": "Koh HK, Geller AC, Miller DR, Grossbart TA, Lew RA. Prevention and early detection strategies for melanoma and skin cancer. Current status. Arch Dermatol. 1996;132(4):436\u2013442.", "ArticleIdList": ["8629848"]}, {"Citation": "Reed KB, Brewer JD, Lohse CM, Bringe KE, Pruitt CN, Gibson LE. Increasing incidence of melanoma among young adults: an epidemiological study in Olmsted County, Minnesota. Mayo Clin Proc. 2012;87(4):328\u2013334.", "ArticleIdList": ["PMC3538462", "22469345"]}, {"Citation": "van der Leun JC, Takizawa Y, Longstreth JD.Human health United Nations Environment Programme Environmental Effects Panel Report Nairobi: United Nations Environment Programme; 198911\u201324.Available from: http://www.ciesin.org/docs/001-538/001-538.htmlAccessed Dec 2012"}, {"Citation": "Woodcock A. The Montreal Protocol: getting over the finishing line? Lancet. 2009;373(9665):705\u2013706.", "ArticleIdList": ["19249618"]}, {"Citation": "Velders GJ, Andersen SO, Daniel JS, Fahey DW, McFarland M. The importance of the Montreal Protocol in protecting climate. Proc Natl Acad Sci USA. 2007;104(12):4814\u20134819.", "ArticleIdList": ["PMC1817831", "17360370"]}, {"Citation": "Anderson SO, Sarma KM, Taddonio KN. Technology Transfer for the Ozone Layer: Lessons for Climate Change. London: Earthscan; 2007. Background of the ozone and climate agreements; pp. 23\u201343."}, {"Citation": "Zeidler M, Corren J. Hydrofluoroalkane formulations of inhaled corticosteroids for the treatment of asthma. Treat Respir Med. 2004;3(1):35\u201344.", "ArticleIdList": ["15174892"]}, {"Citation": "Dockhorn RJ, Wagner DE, Burgess GL, et al. Proventil HFA provides protection from exercise-induced bronchoconstriction comparable to proventil and ventolin. Ann Allergy Asthma Immunol. 1997;79(1):85\u201388.", "ArticleIdList": ["9236507"]}, {"Citation": "Clark A. The physics of aerosol formation by MDIs: limitations of the current approach. J Biopharm Sci. 1992;3(1):69\u201376."}, {"Citation": "Harrison E. Change in the air. Banning CFC-driven inhalers could levy a toll on asthma sufferers. Sci Am. 2008;29920(2):22.", "ArticleIdList": ["18666671"]}, {"Citation": "Newman SP. Principles of metered-dose inhaler design. Respir Care. 2005;50(9):1177\u20131190.", "ArticleIdList": ["16122401"]}, {"Citation": "Dalby RN, Eicher J, Zierenberg B. Development of Respimat(\u00ae) Soft Mist\u2122 Inhaler and its clinical utility in respiratory disorders. Med Devices (Auckl) 2011;4:145\u2013155.", "ArticleIdList": ["PMC3417885", "22915941"]}, {"Citation": "Dalby R, Spallek M, Voshaar T. A review of the development of Respimat Soft Mist Inhaler. Int J Pharm. 2004;283(1\u20132):1\u20139.", "ArticleIdList": ["15363496"]}, {"Citation": "van Noord JA, Smeets JJ, Creemers JP, Greefhorst LP, Dewberry H, Cornelissen PJ. Delivery of fenoterol via Respimat, a novel \u2018soft mist\u2019 inhaler. A randomised, double-blind (within device), placebo-controlled, cross-over, dose-ranging study in asthmatic patients. Respiration. 2000;67(6):672\u2013678.", "ArticleIdList": ["11124651"]}, {"Citation": "Longest PW, Hindle M, Choudhuri SD, Byron PR. Numerical simulations of capillary aerosol generation: CFD model development and comparisons with experimental data. Aerosol Sci Technol. 2007;41(10):952\u2013973."}, {"Citation": "Longest PW, Hindle M, Choudhuri SD, Xi J. Comparison of ambient and spray aerosol deposition in a standard induction port and more realistic mouth\u2013throat geometry. J Aerosol Sci. 2008;39(7):572\u2013591."}, {"Citation": "Newman SP, Pavia D, Mor\u00e9n F, Sheahan NF, Clarke SW. Deposition of pressurised aerosols in the human respiratory tract. Thorax. 1981;36(1):52\u201355.", "ArticleIdList": ["PMC471441", "7292382"]}, {"Citation": "Newman SP. Aerosol deposition considerations in inhalation therapy. Chest. 1985;88(Suppl 2):152S\u2013160S.", "ArticleIdList": ["3893925"]}, {"Citation": "Stein SW, Gabrio BJ. Understanding Throat Deposition During Cascade Impactor Testing. In: RN Dalby, PR Byron, SJ Farr, J Peart., editors. Respiratory Drug Delivery VII. Serentec; Raleigh, NC: 2000. pp. 573\u2013576."}, {"Citation": "Longest PW, Hindle M. Quantitative analysis and design of a spray aerosol inhaler. Part 1: effects of dilution air inlets and flow paths. J Aerosol Med Pulm Drug Deliv. 2009;22(3):271\u2013283.", "ArticleIdList": ["19466904"]}, {"Citation": "Hochrainer D, H\u00f6lz H, Kreher C, Scaffidi L, Spallek M, Wachtel H. Comparison of the aerosol velocity and spray duration of Respimat Soft Mist inhaler and pressurized metered dose inhalers. J Aerosol Med. 2005;18(3):273\u2013282.", "ArticleIdList": ["16181002"]}, {"Citation": "Khachikian D.VA Pharmacy Benefits Management Services, Medical Advisory Panel, VISN Pharmacist Executives Ipratropium/Albuterol (Combivent\u00ae Respimat\u00ae) Abbreviated Review 2012Available from: http://www.pbm.va.gov/ClinicalGuidance/AbbreviatedReviews/Ipratropium-albuterol(CombiventRespimat).docAccessed February 12, 2013"}, {"Citation": "Newman SP, Steed KP, Reader SJ, Hooper G, Zierenberg B. Efficient delivery to the lungs of flunisolide aerosol from a new portable hand-held multidose nebulizer. J Pharm Sci. 1996;85(9):960\u2013964.", "ArticleIdList": ["8877887"]}, {"Citation": "Newman SP, Brown J, Steed KP, Reader SJ, Kladders H. Lung deposition of fenoterol and flunisolide delivered using a novel device for inhaled medicines: comparison of RESPIMAT with conventional metered-dose inhalers with and without spacer devices. Chest. 1998;113(4):957\u2013963.", "ArticleIdList": ["9554631"]}, {"Citation": "Pitcairn G, Reader S, Pavia D, Newman S. Deposition of corticosteroid aerosol in the human lung by Respimat Soft Mist inhaler compared to deposition by metered dose inhaler or by Turbuhaler dry powder inhaler. J Aerosol Med. 2005;18(3):264\u2013272.", "ArticleIdList": ["16181001"]}, {"Citation": "Brand P, Hederer B, Austen G, Dewberry H, Meyer T. Higher lung deposition with Respimat Soft Mist inhaler than HFA-MDI in COPD patients with poor technique. Int J Chron Obstruct Pulmon Dis. 2008;3(4):763\u2013770.", "ArticleIdList": ["PMC2650591", "19281091"]}, {"Citation": "Boehringer Ingelheim Frequently asked questions about COMVIVENT RESPIMAT [web page on the Internet] Ingelheim: Boehringer Ingelheim; Available from: http://www.combivent.com/respimat/faq.htmlAccessed Jan 2013"}, {"Citation": "Zuwallack R, De Salvo MC, Kaelin T, et al. Combivent Respimat Inhaler Study Group Efficacy and safety of ipratropium bromide/albuterol delivered via Respimat inhaler versus MDI. Respir Med. 2010;104(8):1179\u20131188.", "ArticleIdList": ["20172704"]}, {"Citation": "Kilfeather SA, Ponitz HH, Beck E, et al. Improved delivery of ipratropium bromide/fenoterol from Respimat Soft Mist Inhaler in patients with COPD. Respir Med. 2004;98(5):387\u2013397.", "ArticleIdList": ["15139567"]}, {"Citation": "Iacono P, Velicitat P, Guemas E, Leclerc V, Th\u00e9bault JJ. Improved delivery of ipratropium bromide using Respimat (a new soft mist inhaler) compared with a conventional metered dose inhaler: cumulative dose response study in patients with COPD. Respir Med. 2000;94(5):490\u2013495.", "ArticleIdList": ["10868713"]}, {"Citation": "Ram FS, Carvallho CR, White J. Clinical effectiveness of the Respimat inhaler device in managing chronic obstructive pulmonary disease: evidence when compared with other handheld inhaler devices. Int J Chron Obstruct Pulmon Dis. 2011;6:129\u2013139.", "ArticleIdList": ["PMC3064421", "21468167"]}, {"Citation": "Osterberg L, Blaschke T. Adherence to medication. N Engl J Med. 2005;353(5):487\u2013497.", "ArticleIdList": ["16079372"]}, {"Citation": "Hodder R, Reese PR, Slaton T. Asthma patients prefer Respimat Soft Mist Inhaler to Turbuhaler. Int J Chron Obstruct Pulmon Dis. 2009;4:225\u2013232.", "ArticleIdList": ["PMC2699822", "19554196"]}, {"Citation": "Ram FS, Brocklebank DM, Muers M, Wright J, Jones PW. Pressurised metered-dose inhalers versus all other hand-held inhalers devices to deliver bronchodilators for chronic obstructive pulmonary disease. Cochrane Database Syst Rev. 2002(1):CD002170.", "ArticleIdList": ["11869627"]}, {"Citation": "Brocklebank D, Ram F, Wright J, et al. Comparison of the effectiveness of inhaler devices in asthma and chronic obstructive airways disease: a systematic review of the literature. Health Technol Assess. 2001;5(26):1\u2013149.", "ArticleIdList": ["11701099"]}, {"Citation": "Dolovich MB, Ahrens RC, Hess DR, et al. American College of Chest Physicians. American College of Asthma, Allergy, and Immunology Device selection and outcomes of aerosol therapy: Evidence-based guidelines: American College of Chest Physicians/American College of Asthma, Allergy, and Immunology. Chest. 2005;127(1):335\u2013371.", "ArticleIdList": ["15654001"]}, {"Citation": "Welch MJ, Nelson HS, Shapiro G, et al. Comparison of patient preference and ease of teaching inhaler technique for Pulmicort Turbuhaler versus pressurized metered-dose inhalers. J Aerosol Med. 2004;17(2):129\u2013139.", "ArticleIdList": ["15294063"]}, {"Citation": "Kozma CM, Slaton TL, Monz BU, Hodder R, Reese PR. Development and validation of a patient satisfaction and preference questionnaire for inhalation devices. Treat Respir Med. 2005;4(1):41\u201352.", "ArticleIdList": ["15725049"]}, {"Citation": "Monz B, Kozma C, Reese P, Slaton T, Hodder R. Patient Satisfaction and Preference Questionnaire (PASAPQ) User Manual. Boehringer Ingelheim International GmbH; 2005. Brigitta.Monz@ing.Boehringer-ingelheim.com."}, {"Citation": "Hodder R, Price D. Patient preferences for inhaler devices in chronic obstructive pulmonary disease: experience with Respimat Soft Mist inhaler. Int J Chron Obstruct Pulmon Dis. 2009;4:381\u2013390.", "ArticleIdList": ["PMC2829861", "19888356"]}, {"Citation": "Sch\u00fcrmann W, Schmidtmann S, Moroni P, Massey D, Qidan M. Respimat Soft Mist inhaler versus hydrofluoroalkane metered dose inhaler: patient preference and satisfaction. Treat Respir Med. 2005;4(1):53\u201361.", "ArticleIdList": ["15725050"]}, {"Citation": "Singh S, Loke YK, Enright P, Furberg CD. Pro-arrhythmic and pro-ischaemic effects of inhaled anticholinergic medications. Thorax. 2013;68(1):114\u2013116.", "ArticleIdList": ["22764216"]}, {"Citation": "Karner C, Chong J, Poole P. Tiotropium versus placebo for chronic obstructive pulmonary disease. Cochrane Database Syst Rev. 2012(7):CD009285.", "ArticleIdList": ["22786525"]}, {"Citation": "Dong YH, Lin HH, Shau WY, Chang CH, Lai MS. Comparative safety of inhaled medications in patients with chronic obstructive pulmonary disease: systematic review and mixed treatment comparison meta-analysis of randomised controlled trials. Thorax. 2013;68(1):48\u201356.", "ArticleIdList": ["23042705"]}, {"Citation": "Jenkins CR, Beasley R. Tiotropium Respimat increases the risk of mortality. Thorax. 2013;68(1):5\u20137.", "ArticleIdList": ["23229813"]}, {"Citation": "Anthonisen NR, Connett JE, Enright PL, Manfreda J, Lung Health Study Research Group Hospitalizations and mortality in the Lung Health Study. Am J Respir Crit Care Med. 2002;166(3):333\u2013339.", "ArticleIdList": ["12153966"]}, {"Citation": "Macie C, Wooldrage K, Manfreda J, Anthonisen N. Cardiovascular morbidity and the use of inhaled bronchodilators. Int J Chron Obstruct Pulmon Dis. 2008;3(1):163\u2013169.", "ArticleIdList": ["PMC2528211", "18488440"]}, {"Citation": "Singh S, Loke YK, Furberg CD. Inhaled anticholinergics and risk of major adverse cardiovascular events in patients with chronic obstructive pulmonary disease: a systematic review and meta-analysis. JAMA. 2008;300(12):1439\u20131450.", "ArticleIdList": ["18812535"]}, {"Citation": "Ogale SS, Lee TA, Au DH, Boudreau DM, Sullivan SD. Cardiovascular events associated with ipratropium bromide in COPD. Chest. 2010;137(1):13\u201319.", "ArticleIdList": ["19363211"]}, {"Citation": "Wilchesky M, Ernst P, Brophy JM, Platt RW, Suissa S. Bronchodilator use and the risk of arrhythmia in COPD: part 2: reassessment in the larger Quebec cohort. Chest. 2012;142(2):305\u2013311.", "ArticleIdList": ["22871756"]}, {"Citation": "Wang MT, Tsai CL, Lo YW, Liou JT, Lee WJ, Lai IC. Risk of stroke associated with inhaled ipratropium bromide in chronic obstructive pulmonary disease: a population-based nested case-control study. Int J Cardiol. 2012;158(2):279\u2013284.", "ArticleIdList": ["22386700"]}, {"Citation": "Gordon J, Panos RJ. Inhaled albuterol/salbutamol and ipratropium bromide and their combination in the treatment of chronic obstructive pulmonary disease. Expert Opin Drug Metab Toxicol. 2010;6(3):381\u2013392.", "ArticleIdList": ["20163324"]}]}], "History": [{"Year": "2013", "Month": "5", "Day": "10", "Hour": "6", "Minute": "0"}, {"Year": "2013", "Month": "5", "Day": "10", "Hour": "6", "Minute": "0"}, {"Year": "2013", "Month": "11", "Day": "8", "Hour": "6", "Minute": "0"}, {"Year": "2013", "Month": "4", "Day": "30"}], "PublicationStatus": "ppublish", "ArticleIdList": ["23658481", "PMC3643287", "10.2147/COPD.S31246", "copd-8-221"]}}], "PubmedBookArticle": []}